Posaconazole
Clinical data | |
---|---|
Trade names | Noxafil, Posanol, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607036 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Low (8 to 47% Oral) |
Protein binding | 98 to 99% |
Metabolism | Liver (glucuronidation) |
Elimination half-life | 16 to 31 hours |
Excretion | Fecal (71–77%) and Kidney (13–14%) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Posaconazole, sold under the brand name Noxafil among others, is a
It was approved for medical use in the United States in September 2006,
Medical uses
Posaconazole is used to treat invasive Aspergillus and Candida infections.[5] It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole therapy.[5]
It is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients.[12][13]
Clinical evidence for its utility in treatment of invasive disease caused by Fusarium species (fusariosis) is limited.[14]
It appears to be helpful in a
Pharmacology
Pharmacodynamics
Posaconazole works by disrupting the close packing of acyl chains of
Microbiology
Posaconazole is active against the following microorganisms:[16][18]
- Candidaspp.
- Aspergillus spp.
- Zygomycetesspp.
Pharmacokinetics
Posaconazole is absorbed within three to five hours. It is predominantly eliminated through the liver, and has a half-life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state.[5][18]
References
- ^ "Posaconazole (Noxafil) Use During Pregnancy". Drugs.com. 23 April 2019. Archived from the original on 30 January 2020. Retrieved 30 January 2020.
- ^ "Posaconazole suspension ARX/Posaconazole TIH/APX-Posaconazole (Arrow Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
- ^ "Posanol Product information". Health Canada. 25 April 2012. Archived from the original on 16 May 2021. Retrieved 3 July 2022.
- ^ "Noxafil 100 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 January 2022. Archived from the original on 24 February 2022. Retrieved 3 July 2022.
- ^ a b c d e f "Noxafil- posaconazole suspension Noxafil- posaconazole tablet, coated Noxafil- posaconazole solution". DailyMed. 20 March 2020. Archived from the original on 26 February 2021. Retrieved 15 August 2020.
- ^ "Noxafil EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 19 October 2021. Retrieved 3 July 2022.
- PMID 18035188.
- ]
- ^ "Drug Approval Package: Noxafil (Posaconazole) NDA #022003". U.S. Food and Drug Administration (FDA). 9 November 2006. Archived from the original on 3 April 2021. Retrieved 15 August 2020.
- ^ "Posaconazole: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 20 October 2020. Retrieved 15 August 2020.
- ^ "First Generic Drug Approvals". U.S. Food and Drug Administration. 17 October 2022. Archived from the original on 26 January 2021. Retrieved 28 November 2022.
- PMID 14657086.
- (subscription required)
- PMID 16619151.
- PMID 30358879.
- ^ ISBN 978-0-07-142280-2
- ^ "Clinical Pharmacology Posaconazole". Archived from the original on 30 August 2021. Retrieved 18 February 2010.
- ^ a b Ashley ED, Perfect JR (October 2017). "Pharmacology of azoles". In Kauffman CA (ed.). UpToDate. Waltham, MA: UpToDate. Archived from the original on 9 February 2013. Retrieved 18 February 2010.
External links
- Media related to Posaconazole at Wikimedia Commons